Display options
Cite
Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013;18(2):232-8doi: 10.1634/theoncologist.2012-0423.
Schilsky, R. L. (2013). Publicly funded clinical trials and the future of cancer care. The oncologist, 18(2), 232-8. https://doi.org/10.1634/theoncologist.2012-0423
Schilsky, Richard L. "Publicly funded clinical trials and the future of cancer care." The oncologist vol. 18,2 (2013): 232-8. doi: https://doi.org/10.1634/theoncologist.2012-0423
Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013;18(2):232-8. doi: 10.1634/theoncologist.2012-0423. Epub 2013 Jan 30. PMID: 23363807; PMCID: PMC3579608.
Copy Download .nbib Format: NLM
Share it on

Oncologist. 2013;18(2):232-8. doi: 10.1634/theoncologist.2012-0423. Epub 2013 Jan 30.

Publicly funded clinical trials and the future of cancer care.

The oncologist

Richard L Schilsky

Affiliations

  1. Section of Hematology-Oncology, The University of Chicago, Chicago, Illinois, USA. [email protected]

PMID: 23363807 PMCID: PMC3579608 DOI: 10.1634/theoncologist.2012-0423

Abstract

Publicly sponsored trials, conducted primarily by cooperative groups sponsored by the National Cancer Institute, and commercially sponsored trials are necessary to create new knowledge, improve the care of oncology patients, and develop new drugs and devices. Commercial sponsors launch clinical trials that will result in drug approval, label extension, expansion of market share, and an increase in shareholder value. Conversely, publicly sponsored trials seek to optimize therapy for a particular disease, create new knowledge, and improve public health; these trials can also result in label extension of a drug and even in initial drug approval. Publicly sponsored trials may combine and/or compare drugs developed by different commercial sponsors, develop multimodality therapies (e.g., the combination of chemotherapy and radiation), or develop novel treatment schedules or routes of drug administration (e.g., intraperitoneal chemotherapy). Publicly sponsored trials are more likely to focus on therapies for rare diseases and to study survivorship and quality of life; these areas may not be a priority for commercial entities. Screening and prevention strategies have been developed almost exclusively by the public sector given the large sample size and long follow-up period needed to complete the trial and, therefore, the lack of short-term commercial gain. Finally, given the public nature of the funding, clinical investigators are expected to publish their results even if the outcomes are unfavorable for the investigational therapy. With the ongoing reorganization of the cooperative groups to form a national clinical trials network, opportunities exist to create a robust platform for biomarker discovery and validation through the expanded collection of well-annotated biospecimens obtained from clinical trial participants. Thus, publicly funded trials are vital to developing and refining new cancer treatments and disseminating results to the medical community and the general public.

References

  1. J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92 - PubMed
  2. J Clin Oncol. 2002 May 15;20(10):2429-40 - PubMed
  3. JAMA. 2006 Jun 21;295(23):2727-41 - PubMed
  4. J Natl Cancer Inst. 2010 Sep 8;102(17):1371 - PubMed
  5. J Clin Oncol. 2008 Feb 20;26(6):848-55 - PubMed
  6. N Engl J Med. 2002 Jan 10;346(2):92-8 - PubMed
  7. J Clin Oncol. 2012 Jul 1;30(19):2327-33 - PubMed
  8. Cancer Res. 2001 Oct 1;61(19):7233-9 - PubMed
  9. N Engl J Med. 1993 Apr 8;328(14):1002-6 - PubMed
  10. Clin Cancer Res. 2012 Mar 15;18(6):1540-6 - PubMed
  11. N Engl J Med. 2004 Sep 2;351(10):971-7 - PubMed
  12. Semin Oncol. 2008 Oct;35(5):484-93 - PubMed
  13. N Engl J Med. 2006 Jan 5;354(1):34-43 - PubMed
  14. Cancer. 2010 Oct 1;116(19):4440-9 - PubMed
  15. J Clin Oncol. 2003 Apr 15;21(8):1431-9 - PubMed
  16. N Engl J Med. 2004 May 13;350(20):2050-9 - PubMed
  17. Arch Surg. 2008 Sep;143(9):832-9; discussion 839-40 - PubMed
  18. J Clin Oncol. 2005 Apr 1;23(10):2191-200 - PubMed
  19. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706 - PubMed
  20. N Engl J Med. 2003 Nov 27;349(22):2091-8 - PubMed
  21. J Clin Oncol. 2012 May 10;30(14):1601-7 - PubMed
  22. J Clin Oncol. 2007 Jul 20;25(21):3061-8 - PubMed
  23. Clin Cancer Res. 2012 Feb 1;18(3):890-900 - PubMed
  24. J Clin Oncol. 2013 May 10;31(14):1775-81 - PubMed
  25. Clin Cancer Res. 2009 Dec 1;15(23):7322-9 - PubMed

MeSH terms

Publication Types